# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BDRX: 110% | Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatou...
https://www.sec.gov/ix?doc=/Archives/edgar/data/1517375/000151737524000075/spt-20240520.htm
- Reuters Exclusive
Needham analyst Scott Berg reiterates Sprout Social (NASDAQ:SPT) with a Buy and maintains $55 price target.
Goldman Sachs analyst Chris Merwin maintains Sprout Social (NASDAQ:SPT) with a Neutral and lowers the price target from $80 ...
Shares of Sprout Social fell Friday after reporting first-quarter financial results Thursday and sharing Q2 guidance.Cloud soft...
Canaccord Genuity analyst David Hynes maintains Sprout Social (NASDAQ:SPT) with a Buy and lowers the price target from $70 t...